+

WO2003004602A3 - Nuclease resistant chimeric oligonucleotides - Google Patents

Nuclease resistant chimeric oligonucleotides Download PDF

Info

Publication number
WO2003004602A3
WO2003004602A3 PCT/US2002/020934 US0220934W WO03004602A3 WO 2003004602 A3 WO2003004602 A3 WO 2003004602A3 US 0220934 W US0220934 W US 0220934W WO 03004602 A3 WO03004602 A3 WO 03004602A3
Authority
WO
WIPO (PCT)
Prior art keywords
oligomeric compounds
chimeric oligonucleotides
nuclease resistant
oligomeric
nuclease
Prior art date
Application number
PCT/US2002/020934
Other languages
French (fr)
Other versions
WO2003004602A2 (en
Inventor
Muthiah Manoharan
Martin A Maier
Thazha P Prakash
Kallanthottathil Gopala Rajeev
Original Assignee
Isis Pharmaceuticals Inc
Muthiah Manoharan
Martin A Maier
Thazha P Prakash
Kallanthottathil Gopala Rajeev
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/996,292 external-priority patent/US20030158403A1/en
Priority claimed from US10/013,295 external-priority patent/US20030175906A1/en
Application filed by Isis Pharmaceuticals Inc, Muthiah Manoharan, Martin A Maier, Thazha P Prakash, Kallanthottathil Gopala Rajeev filed Critical Isis Pharmaceuticals Inc
Priority to CA002452458A priority Critical patent/CA2452458A1/en
Priority to EP02746811A priority patent/EP1499627A2/en
Priority to JP2003510761A priority patent/JP2005504020A/en
Publication of WO2003004602A2 publication Critical patent/WO2003004602A2/en
Publication of WO2003004602A3 publication Critical patent/WO2003004602A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Saccharide Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention relates to novel nuclease-resistant oligomeric compounds and to novel methods for increasing resistance of oligomeric compounds. In preferred embodiments of the invention, the oligomeric compounds comprise at least one modified nucleoside containing a modified sugar moiety at either the 3' or 5' terminus of the oligomeric compound, and further comprise at least one internucleoside linking group that is other than phosphodiester. Other preferred embodiments of the invention include methods of enhancing the nuclease resistance of oligomeric compounds comprising incorporating at least one modified nucleoside containing a modified sugar moiety at either the 3' or 5' terminus of an oligomeric compound.
PCT/US2002/020934 2001-07-03 2002-07-01 Nuclease resistant chimeric oligonucleotides WO2003004602A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
CA002452458A CA2452458A1 (en) 2001-07-03 2002-07-01 Nuclease resistant chimeric oligonucleotides
EP02746811A EP1499627A2 (en) 2001-07-03 2002-07-01 Nuclease resistant chimeric oligonucleotides
JP2003510761A JP2005504020A (en) 2001-07-03 2002-07-01 Nuclease resistant chimeric oligonucleotide

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US30268201P 2001-07-03 2001-07-03
US60/302,682 2001-07-03
US09/996,292 US20030158403A1 (en) 2001-07-03 2001-11-28 Nuclease resistant chimeric oligonucleotides
US09/996,292 2001-11-28
US10/013,295 2001-12-10
US10/013,295 US20030175906A1 (en) 2001-07-03 2001-12-10 Nuclease resistant chimeric oligonucleotides

Publications (2)

Publication Number Publication Date
WO2003004602A2 WO2003004602A2 (en) 2003-01-16
WO2003004602A3 true WO2003004602A3 (en) 2004-11-18

Family

ID=27359825

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/020934 WO2003004602A2 (en) 2001-07-03 2002-07-01 Nuclease resistant chimeric oligonucleotides

Country Status (4)

Country Link
EP (1) EP1499627A2 (en)
JP (1) JP2005504020A (en)
CA (1) CA2452458A1 (en)
WO (1) WO2003004602A2 (en)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8846639B2 (en) 2008-04-04 2014-09-30 Isis Pharmaceutical, Inc. Oligomeric compounds comprising bicyclic nucleosides and having reduced toxicity
US9150606B2 (en) 2002-11-05 2015-10-06 Isis Pharmaceuticals, Inc. Compositions comprising alternating 2'-modified nucleosides for use in gene modulation
US9175291B2 (en) 2012-10-11 2015-11-03 Isis Pharmaceuticals Inc. Modulation of androgen receptor expression
US9382540B2 (en) 2014-05-01 2016-07-05 Isis Pharmaceuticals, Inc Compositions and methods for modulating angiopoietin-like 3 expression
US9399774B2 (en) 2010-04-29 2016-07-26 Ionis Pharmaceuticals, Inc. Modulation of transthyretin expression
US9598693B2 (en) 2006-01-27 2017-03-21 Ionis Pharmaceuticals, Inc. Oligomeric compounds and compositions for the use in modulation of micrornas
US11851655B2 (en) 2013-05-01 2023-12-26 Ionis Pharmaceuticals, Inc. Compositions and methods for modulating apolipoprotein (a) expression

Families Citing this family (146)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9096636B2 (en) 1996-06-06 2015-08-04 Isis Pharmaceuticals, Inc. Chimeric oligomeric compounds and their use in gene modulation
US7812149B2 (en) 1996-06-06 2010-10-12 Isis Pharmaceuticals, Inc. 2′-Fluoro substituted oligomeric compounds and compositions for use in gene modulations
US5898031A (en) 1996-06-06 1999-04-27 Isis Pharmaceuticals, Inc. Oligoribonucleotides for cleaving RNA
US7098192B2 (en) 1999-04-08 2006-08-29 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of STAT3 expression
US20050019915A1 (en) 2001-06-21 2005-01-27 Bennett C. Frank Antisense modulation of superoxide dismutase 1, soluble expression
EP2270024B1 (en) 2001-06-21 2018-10-24 Ionis Pharmaceuticals, Inc. Antisense modulation of superoxide dismutase 1, soluble expression
CA2452458A1 (en) * 2001-07-03 2003-01-16 Isis Pharmaceuticals, Inc. Nuclease resistant chimeric oligonucleotides
US7425545B2 (en) 2001-07-25 2008-09-16 Isis Pharmaceuticals, Inc. Modulation of C-reactive protein expression
US9150605B2 (en) 2002-11-05 2015-10-06 Isis Pharmaceuticals, Inc. Compositions comprising alternating 2′-modified nucleosides for use in gene modulation
CA2504929C (en) 2002-11-05 2014-07-22 Charles Allerson Compositions comprising alternating 2'-modified nucleosides for use in gene modulation
BRPI0410886A (en) 2003-06-03 2006-07-04 Isis Pharmaceuticals Inc double stranded compound, pharmaceutical composition, pharmaceutically acceptable salt, methods of modifying human survivin-encoding nucleic acid, inhibiting suvivin expression in cells or tissues, and treating a condition associated with suvivin expression or overexpression, and single stranded RNA oligonucleotide
EP1648914A4 (en) 2003-07-31 2009-12-16 Regulus Therapeutics Inc Oligomeric compounds and compositions for use in modulation of small non-coding rnas
US7825235B2 (en) 2003-08-18 2010-11-02 Isis Pharmaceuticals, Inc. Modulation of diacylglycerol acyltransferase 2 expression
EP1668130A2 (en) 2003-09-18 2006-06-14 Isis Pharmaceuticals, Inc. Modulation of eif4e expression
US8569474B2 (en) 2004-03-09 2013-10-29 Isis Pharmaceuticals, Inc. Double stranded constructs comprising one or more short strands hybridized to a longer strand
US8394947B2 (en) 2004-06-03 2013-03-12 Isis Pharmaceuticals, Inc. Positionally modified siRNA constructs
US7884086B2 (en) 2004-09-08 2011-02-08 Isis Pharmaceuticals, Inc. Conjugates for use in hepatocyte free uptake assays
US8153603B2 (en) 2005-02-25 2012-04-10 Isis Pharmaceuticals, Inc. Compositions and their uses directed to IL-4R alpha
EP1931782B2 (en) 2005-08-29 2016-04-20 Regulus Therapeutics Inc Methods for use in modulating mir-122a
US20090203893A1 (en) 2005-08-29 2009-08-13 Regulus Therapeutics, Llc Antisense compounds having enhanced anti-microrna activity
TW200838551A (en) 2006-11-27 2008-10-01 Isis Pharmaceuticals Inc Methods for treating hypercholesterolemia
EP2641971A1 (en) 2007-01-29 2013-09-25 Isis Pharmaceuticals, Inc. Compounds and methods for modulating protein expression
MX2009012568A (en) 2007-05-22 2009-12-08 Mdrna Inc Hydroxymethyl substituted rna oligonucleotides and rna complexes.
JP5792955B2 (en) 2007-10-01 2015-10-14 アイシス ファーマシューティカルズ， インコーポレーテッド Antisense modulation of fibroblast growth factor receptor 4 expression
EP2205741A2 (en) 2007-10-02 2010-07-14 Amgen Inc. Increasing erythropoietin using nucleic acids hybridizable to micro-rna and precursors thereof
BRPI0817605A2 (en) * 2007-10-03 2017-05-09 Quark Pharmaceuticals Inc new siren structures
JP2011502514A (en) 2007-11-09 2011-01-27 アイシス ファーマシューティカルズ インコーポレイティッド Regulation of factor 7 expression
WO2009143390A2 (en) 2008-05-22 2009-11-26 Isis Pharmaceuticals, Inc. Methods for modulating expression of rbp4
US8541387B2 (en) 2008-05-22 2013-09-24 Isis Pharmaceuticals, Inc. Modulation of SMRT expression
CA2740785C (en) 2008-10-15 2017-06-20 Isis Pharmaceuticals, Inc. Modulation of factor 11 expression
US8987435B2 (en) 2008-10-24 2015-03-24 Isis Pharmaceuticals, Inc. Oligomeric compounds and methods
CN102282155B (en) 2008-12-02 2017-06-09 日本波涛生命科学公司 The synthetic method of the nucleic acid of phosphorus atoms modification
BRPI0922355A8 (en) * 2008-12-03 2017-12-12 Marina Biotech Inc NUCLEIC ACIDS, METHODS FOR REDUCING EXPRESSION OF A GENE IN A CELL IN VITRO, USE OF NUCLEIC ACID, RNA COMPLEX AND USE OF RNA COMPLEX
EP2393825A2 (en) 2009-02-06 2011-12-14 Isis Pharmaceuticals, Inc. Oligomeric compounds and methods
EP2408796B1 (en) 2009-03-16 2020-04-22 Ionis Pharmaceuticals, Inc. Targeting Apolipoprotein B for the reduction of Apolipoprotein C-III
MX361732B (en) 2009-06-17 2018-12-14 Cold Spring Harbor Laboratory Compositions and methods for modulation of smn2 splicing in a subject.
KR101885383B1 (en) 2009-07-06 2018-08-03 웨이브 라이프 사이언시스 리미티드 Novel nucleic acid prodrugs and methods of use thereof
EP3178933B1 (en) 2009-09-11 2019-11-13 Ionis Pharmaceuticals, Inc. Modulation of huntingtin expression
TWI589294B (en) * 2009-10-16 2017-07-01 梅林塔療法公司 Antimicrobial compound and its manufacture and use method
US9023843B2 (en) 2009-10-16 2015-05-05 Melinta Therapeutics, Inc. Antimicrobial compounds and methods of making and using the same
EA023350B1 (en) 2009-10-16 2016-05-31 Мелинта Терапьютикс, Инк. Antimicrobial compounds, methods of making and using the same
WO2011085271A2 (en) 2010-01-08 2011-07-14 Isis Pharmaceuticals, Inc. Modulation of angiopoietin-like 3 expression
ES2733708T3 (en) 2010-02-08 2019-12-02 Ionis Pharmaceuticals Inc Selective reduction of allelic variants
EP3628750A1 (en) 2010-02-08 2020-04-01 Ionis Pharmaceuticals, Inc. Selective reduction of allelic variants
US20130156845A1 (en) 2010-04-29 2013-06-20 Alnylam Pharmaceuticals, Inc. Lipid formulated single stranded rna
KR101900770B1 (en) 2010-07-19 2018-09-20 아이오니스 파마수티컬즈, 인코포레이티드 Modulation of dystrophia myotonica-protein kinase (dmpk) expression
JP5868324B2 (en) 2010-09-24 2016-02-24 株式会社Ｗａｖｅ Ｌｉｆｅ Ｓｃｉｅｎｃｅｓ Ｊａｐａｎ Asymmetric auxiliary group
WO2012064758A2 (en) 2010-11-08 2012-05-18 Isis Pharmaceuticals, Inc. Methods for modulating factor 12 expression
CA3077910A1 (en) 2010-11-17 2012-05-24 Ionis Pharmaceuticals, Inc. Modulation of alpha synuclein expression
GB201021867D0 (en) * 2010-12-23 2011-02-02 Mologen Ag Non-coding immunomodulatory DNA construct
MX340086B (en) 2011-04-01 2016-06-24 Ionis Pharmaceuticals Inc Modulation of signal transducer and activator of transcription 3 (stat3) expression.
PE20141177A1 (en) 2011-04-21 2014-09-19 Isis Pharmaceuticals Inc MODULATION OF THE EXPRESSION OF THE HEPATITIS B VIRUS (HBV)
KR20190062511A (en) 2011-04-27 2019-06-05 아이오니스 파마수티컬즈, 인코포레이티드 Modulation of apolipoprotein ciii (apociii) expression
US9187749B2 (en) 2011-06-10 2015-11-17 Isis Pharmaceuticals, Inc. Methods for modulating factor 12 expression
EP3320922A1 (en) 2011-06-10 2018-05-16 Ionis Pharmaceuticals, Inc. Methods for modulating kallikrein (klkb1) expression
EP2721156B1 (en) 2011-06-16 2016-12-21 Ionis Pharmaceuticals, Inc. Antisense modulation of fibroblast growth factor receptor 4 expression
US9322021B2 (en) 2011-06-29 2016-04-26 Ionis Pharmaceuticals, Inc. Methods for modulating kallikrein (KLKB1) expression
ES2626488T3 (en) 2011-07-19 2017-07-25 Wave Life Sciences Pte. Ltd. Procedures for the synthesis of functionalized nucleic acids
EP2742136B1 (en) 2011-08-11 2017-09-27 Ionis Pharmaceuticals, Inc. Gapped oligomeric compounds comprising 5'-modified deoxyribonucleosides in the gap and uses thereof
EP3401401B1 (en) 2011-09-20 2020-04-15 Ionis Pharmaceuticals, Inc. Antisense modulation of gcgr expression
JP2015501155A (en) 2011-10-25 2015-01-15 アイシス ファーマシューティカルズ， インコーポレーテッド Antisense regulation of GCCR expression
EP3650544A1 (en) 2011-11-07 2020-05-13 Ionis Pharmaceuticals, Inc. Modulation of tmprss6 expression
JP2015502365A (en) 2011-12-12 2015-01-22 オンコイミューニン，インコーポレイティド In vivo delivery of oligonucleotides
CA2859729C (en) 2011-12-22 2021-03-09 Isis Pharmaceuticals, Inc. Methods for modulating metastasis-associated-in-lung-adenocarcinoma-transcript-1(malat-1) expression
EP3330278A1 (en) 2012-02-08 2018-06-06 Ionis Pharmaceuticals, Inc. Modulation of rna by repeat targeting
JP6492003B2 (en) 2012-03-30 2019-03-27 ワシントン・ユニバーシティＷａｓｈｉｎｇｔｏｎ Ｕｎｉｖｅｒｓｉｔｙ Methods of modulating tau expression to reduce stroke and to modify neurodegenerative syndrome
WO2013173789A2 (en) 2012-05-17 2013-11-21 Isis Pharmaceuticals, Inc. Antisense oligonucleotide compositions
US9574193B2 (en) 2012-05-17 2017-02-21 Ionis Pharmaceuticals, Inc. Methods and compositions for modulating apolipoprotein (a) expression
US9518261B2 (en) 2012-05-22 2016-12-13 Ionis Pharmaceuticals, Inc. Modulation of enhancer RNA mediated gene expression
NZ631071A (en) 2012-05-24 2017-02-24 Ionis Pharmaceuticals Inc Methods and compositions for modulating apolipoprotein(a) expression
US9617539B2 (en) 2012-06-25 2017-04-11 Ionis Pharmaceuticals, Inc. Modulation of UBE3A-ATS expression
SG11201500239VA (en) 2012-07-13 2015-03-30 Wave Life Sciences Japan Asymmetric auxiliary group
KR101835401B1 (en) 2012-07-13 2018-03-08 신 니뽄 바이오메디칼 라보라토리즈, 엘티디. Chiral nucleic acid adjuvant
SG10201912895PA (en) 2012-07-13 2020-02-27 Wave Life Sciences Ltd Chiral control
EP2877579B1 (en) 2012-07-27 2019-12-18 Ionis Pharmaceuticals, Inc. Modulation of renin-angiotensin system (ras) related diseases by angiotensinogen
EP4052709A1 (en) 2012-10-11 2022-09-07 Ionis Pharmaceuticals, Inc. Methods of treating kennedy's disease
EP2906258A4 (en) 2012-10-15 2016-08-10 Ionis Pharmaceuticals Inc Compositions for modulating c9orf72 expression
EP2906697A4 (en) 2012-10-15 2016-06-22 Ionis Pharmaceuticals Inc METHODS OF MONITORING C9ORF72 EXPRESSION
PT2906696T (en) 2012-10-15 2019-12-16 Univ California Methods for modulating c9orf72 expression
PT2920308T (en) 2012-10-31 2019-03-20 Ionis Pharmaceuticals Inc Cancer treatment
AU2014216137B2 (en) 2013-02-14 2018-05-10 Ionis Pharmaceuticals, Inc. Modulation of Apolipoprotein C-III (ApoCIII) expression in lipoprotein lipase deficient (LPLD) populations
AU2014236156C1 (en) 2013-03-14 2020-12-17 Ionis Pharmaceuticals, Inc. Compositions and methods for modulating Tau expression
US10590412B2 (en) 2013-04-19 2020-03-17 Ionis Pharmaceuticals, Inc. Compositions and methods for modulation nucleic acids through nonsense mediated decay
EP3656386A1 (en) 2013-06-21 2020-05-27 Ionis Pharmaceuticals, Inc. Compounds and methods for modulating apolipoprotein c-iii expression for improving a diabetic profile
AU2014284398B2 (en) 2013-07-02 2019-10-31 Ionis Pharmaceuticals, Inc. Modulators of growth hormone receptor
TWI657819B (en) 2013-07-19 2019-05-01 美商Ionis製藥公司 Composition for regulating the expression of tau protein
TW201536329A (en) 2013-08-09 2015-10-01 Isis Pharmaceuticals Inc Compound and method for regulating the manifestation of dystrophic myotonic protein kinase (DMPK)
NZ716816A (en) 2013-08-28 2022-05-27 Ionis Pharmaceuticals Inc Modulation of prekallikrein (pkk) expression
EP3038623A4 (en) 2013-09-09 2017-04-19 Melinta Therapeutics, Inc. Antimicrobial compounds and methods of making and using the same
EP3039025A4 (en) 2013-09-09 2017-05-31 Melinta Therapeutics, Inc. Antimicrobial compounds and methods of making and using the same
PE20190354A1 (en) 2013-09-13 2019-03-07 Ionis Pharmaceuticals Inc COMPLEMENT B FACTOR MODULATORS
EP4166667A3 (en) 2013-10-11 2023-08-02 Ionis Pharmaceuticals, Inc. Compositions for modulating c9orf72 expression
US20170037409A1 (en) 2013-12-24 2017-02-09 Ionis Pharmaceuticals, Inc. Modulation of angiopoietin-like 3 expression
EP3095460A4 (en) 2014-01-15 2017-08-23 Shin Nippon Biomedical Laboratories, Ltd. Chiral nucleic acid adjuvant having anti-allergic activity, and anti-allergic agent
WO2015108047A1 (en) 2014-01-15 2015-07-23 株式会社新日本科学 Chiral nucleic acid adjuvant having immunity induction activity, and immunity induction activator
WO2015108048A1 (en) 2014-01-15 2015-07-23 株式会社新日本科学 Chiral nucleic acid adjuvant having antitumor effect and antitumor agent
CA2936712A1 (en) 2014-01-16 2015-07-23 Meena Chiral design
JP6902869B2 (en) 2014-03-19 2021-07-14 アイオーニス ファーマシューティカルズ， インコーポレーテッドＩｏｎｉｓ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． Composition for regulating the expression of ataxin 2
EP3122365B1 (en) 2014-03-25 2023-05-03 Arcturus Therapeutics, Inc. Transthyretin allele selective una oligomers for gene silencing
AU2015236215B2 (en) 2014-03-25 2020-03-19 Arcturus Therapeutics, Inc. UNA oligomers having reduced off-target effects in gene silencing
US9856475B2 (en) 2014-03-25 2018-01-02 Arcturus Therapeutics, Inc. Formulations for treating amyloidosis
SI3126499T1 (en) 2014-04-01 2020-09-30 Biogen Ma Inc. Compositions for modulating sod-1 expression
EP3797780B1 (en) 2014-04-17 2022-09-14 Biogen MA Inc. Compositions and methods for modulation of smn2 splicing in a subject
DK3137604T3 (en) 2014-05-01 2020-08-03 Ionis Pharmaceuticals Inc COMPOSITIONS AND METHODS FOR MODULATION OF GROWTH HORMONE RECEPTOR EXPRESSION
ES2849600T3 (en) 2014-05-01 2021-08-19 Ionis Pharmaceuticals Inc Modified antisense oligonucleotide conjugates and their use to modulate PKK expression
CA2943894A1 (en) 2014-05-01 2015-11-05 Ionis Pharmaceuticals, Inc. Compositions and methods for modulating complement factor b expression
AU2015272128B2 (en) 2014-06-10 2021-10-28 Erasmus University Medical Center Rotterdam Antisense oligonucleotides useful in treatment of Pompe disease
WO2016086104A1 (en) 2014-11-25 2016-06-02 Ionis Pharmaceuticals, Inc. Modulation of ube3a-ats expression
US10426789B2 (en) 2015-02-26 2019-10-01 Ionis Pharmaceuticals, Inc. Allele specific modulators of P23H rhodopsin
EP3265564B1 (en) 2015-03-03 2022-01-26 Ionis Pharmaceuticals, Inc. Methods for modulating mecp2 expression
WO2016141236A1 (en) 2015-03-03 2016-09-09 Ionis Pharmaceuticals, Inc. Compositions for modulating mecp2 expression
EA201792006A1 (en) 2015-03-11 2018-04-30 Мелинта Терапьютикс, Инк. ANTIMICROBIAL COMPOUNDS AND METHODS FOR THEIR PRODUCTION AND THEIR APPLICATION
JP6830441B2 (en) 2015-04-01 2021-02-17 アークトゥラス・セラピューティクス・インコーポレイテッドＡｒｃｔｕｒｕｓ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． Therapeutic UNA oligomers and their use
RU2017137410A (en) 2015-04-03 2019-05-06 Ионис Фармасьютикалз, Инк. CONNECTIONS AND METHODS OF MODELING THE EXPRESSION OF TMPRSS6
MY181815A (en) 2015-04-16 2021-01-08 Ionis Pharmaceuticals Inc Compositions for modulating c9orf72 expression
WO2017015671A1 (en) 2015-07-23 2017-01-26 Arcturus Therapeutics, Inc. Compositions for treating amyloidosis
LU92821B1 (en) 2015-09-09 2017-03-20 Mologen Ag Combination comprising immunostimulatory oligonucleotides
GB2542425A (en) 2015-09-21 2017-03-22 Mologen Ag Means for the treatment of HIV
JP2018530325A (en) 2015-10-08 2018-10-18 アイオーニス ファーマシューティカルズ， インコーポレーテッドＩｏｎｉｓ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． Compounds and methods for modulating the expression of angiotensinogen
US11260073B2 (en) 2015-11-02 2022-03-01 Ionis Pharmaceuticals, Inc. Compounds and methods for modulating C90RF72
CN108348478A (en) 2015-11-06 2018-07-31 Ionis 制药公司 Apolipoprotein (a) is adjusted to express
WO2017099579A1 (en) 2015-12-07 2017-06-15 Erasmus University Medical Center Rotterdam Enzymatic replacement therapy and antisense therapy for pompe disease
CA3023317A1 (en) 2016-05-06 2017-11-09 Melinta Therapeutics, Inc. Antimicrobials and methods of making and using same
WO2018013999A1 (en) 2016-07-15 2018-01-18 Am Chemicals Llc Non-nucleosidic solid supports and phosphoramidite building blocks for oligonucleotide synthesis
NL2017294B1 (en) 2016-08-05 2018-02-14 Univ Erasmus Med Ct Rotterdam Natural cryptic exon removal by pairs of antisense oligonucleotides.
NL2017295B1 (en) 2016-08-05 2018-02-14 Univ Erasmus Med Ct Rotterdam Antisense oligomeric compound for Pompe disease
JOP20190065A1 (en) 2016-09-29 2019-03-28 Ionis Pharmaceuticals Inc Compounds and methods for reducing tau expression
US11401519B2 (en) 2017-06-07 2022-08-02 University Of Massachusetts Anti-ADAM33 oligonucleotides and related methods
TWI809004B (en) 2017-11-09 2023-07-21 美商Ionis製藥公司 Compounds and methods for reducing snca expression
US12241065B2 (en) 2018-01-12 2025-03-04 Bristol-Myers Squibb Company Antisense oligonucleotides targeting alpha-synuclein and uses thereof
EP3737387A1 (en) 2018-01-12 2020-11-18 Bristol-Myers Squibb Company Antisense oligonucleotides targeting alpha-synuclein and uses thereof
KR20210008498A (en) 2018-05-09 2021-01-22 아이오니스 파마수티컬즈, 인코포레이티드 Compounds and methods for reducing FXI expression
CN112566640A (en) 2018-06-18 2021-03-26 罗切斯特大学 Methods of treating schizophrenia and other neuropsychiatric disorders
CN113728103B (en) 2018-12-11 2025-02-28 罗切斯特大学 Methods of treating schizophrenia and other neuropsychiatric disorders
TW202035694A (en) 2018-12-14 2020-10-01 美商百健Ｍａ公司 Compositions and methods for treating and preventing amyotrophic lateral sclerosis
US11279932B2 (en) 2019-02-27 2022-03-22 Ionis Pharmaceuticals, Inc. Modulators of MALAT1 expression
JPWO2020203880A1 (en) 2019-03-29 2020-10-08
EP3947684B1 (en) 2019-03-29 2025-04-09 Ionis Pharmaceuticals, Inc. Compounds and methods for modulating ube3a-ats
RU2731381C1 (en) * 2019-04-26 2020-09-02 Федеральное государственное бюджетное учреждение науки институт биоорганической химии им. академиков М.М. Шемякина и Ю.А. Овчинникова Российской академии наук (ИБХ РАН) Nucleoside derivatives of 1,3-diaza-2-oxophenoxazine as herpesvirus replication inhibitors
CN114072501A (en) 2019-05-06 2022-02-18 马萨诸塞大学 anti-C9 ORF72 oligonucleotides and related methods
KR20220019259A (en) 2019-06-06 2022-02-16 어비디티 바이오사이언시스 인크. UNA amidite and uses thereof
WO2021142245A1 (en) 2020-01-10 2021-07-15 Translate Bio, Inc. Compounds, pharmaceutical compositions and methods for modulating expression of muc5b in lung cells and tissues
WO2021154705A1 (en) 2020-01-27 2021-08-05 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Rab13 and net1 antisense oligonucleotides to treat metastatic cancer
IL302817A (en) 2020-11-18 2023-07-01 Ionis Pharmaceuticals Inc Compounds and methods for modulating angiotensinogen expression
MX2023007257A (en) 2020-12-18 2023-07-03 Ionis Pharmaceuticals Inc Compounds and methods for modulating factor xii.
KR20230172502A (en) 2021-03-31 2023-12-22 바이오젠 엠에이 인코포레이티드 Treatment of amyotrophic lateral sclerosis

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992002534A2 (en) * 1990-08-03 1992-02-20 Sterling Drug, Inc. Compounds and methods for inhibiting gene expression
WO1992003464A1 (en) * 1990-08-28 1992-03-05 Microprobe Corporation Solid support synthesis of 3'-tailed oligonucleotides via a linking molecule
WO1995025814A1 (en) * 1994-03-18 1995-09-28 Lynx Therapeutics, Inc. Oligonucleotide n3'→p5' phosphoramidates: synthesis and compounds; hybridization and nuclease resistance properties
WO1995026972A1 (en) * 1994-03-31 1995-10-12 Amgen Inc. Modified oligonucleotides and intermediates useful in nucleic acid therapeutics
WO1999024452A2 (en) * 1997-11-07 1999-05-20 Isis Pharmaceuticals, Inc. Pyrimidine derivatives for labeled binding partners
WO2001057188A2 (en) * 2000-02-03 2001-08-09 Hyseq, Inc. Novel nucleic acids and polypeptides
WO2003004602A2 (en) * 2001-07-03 2003-01-16 Isis Pharmaceuticals, Inc. Nuclease resistant chimeric oligonucleotides

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992002534A2 (en) * 1990-08-03 1992-02-20 Sterling Drug, Inc. Compounds and methods for inhibiting gene expression
WO1992003464A1 (en) * 1990-08-28 1992-03-05 Microprobe Corporation Solid support synthesis of 3'-tailed oligonucleotides via a linking molecule
WO1995025814A1 (en) * 1994-03-18 1995-09-28 Lynx Therapeutics, Inc. Oligonucleotide n3'→p5' phosphoramidates: synthesis and compounds; hybridization and nuclease resistance properties
WO1995026972A1 (en) * 1994-03-31 1995-10-12 Amgen Inc. Modified oligonucleotides and intermediates useful in nucleic acid therapeutics
WO1999024452A2 (en) * 1997-11-07 1999-05-20 Isis Pharmaceuticals, Inc. Pyrimidine derivatives for labeled binding partners
WO2001057188A2 (en) * 2000-02-03 2001-08-09 Hyseq, Inc. Novel nucleic acids and polypeptides
WO2003004602A2 (en) * 2001-07-03 2003-01-16 Isis Pharmaceuticals, Inc. Nuclease resistant chimeric oligonucleotides

Non-Patent Citations (10)

* Cited by examiner, † Cited by third party
Title
BARAWKAR ET AL: "Synthesis, biophysical properties, and nuclease resistance properties of mixed backbone oligodeoxynucleotides containing cationic internucleoside guanidinium linkages: Deoxynucleic guanidine/DNA chimeras", PNAS, vol. 95, September 1998 (1998-09-01), pages 11047 - 11052, XP002979594 *
CAULFIELD ET AL: "Achiral internucleoside linkages: CH2-CH2-NH and nH-CH2-CH2 linkages", BIOORGANIC AND MEDICINAL CHEMISTRY LETTERS, vol. 3, no. 12, March 1993 (1993-03-01), pages 2771 - 2776, XP002979595 *
HIRAO ET AL: "Most compact hairpin-turn structure exerted by a short DNA fragment, d(GCGAAGC) in solution: and extraordinarily stable structure resistant to nucleases and heat", NUCLEIC ACIDS RESEARCH, vol. 22, no. 4, January 1994 (1994-01-01), pages 576 - 582, XP002980322 *
KARPEISKI ET AL: "Substrate specificity of nuclease S1 from aspergilus oryzae in hydrolysis of low molecular weight substrates", BIOORGANICHESKAYA KHIMIYA, vol. 8, no. 3, January 1982 (1982-01-01), pages 386 - 395, XP001199634 *
KUZNETSOVA ET AL: "Hybridization properties and nuclease resistance of oligo(2'-O-tetrahydropyranylribonucleotides)", RUSSIAN J. OF BIOORGANIC CHEMISTRY, vol. 26, no. 1, January 2000 (2000-01-01), pages 69 - 70, XP008035031 *
PEYROTTES ET AL: "Synthesis, base paiing properties and nuclease resistance of oligothymidylate analogs containing methoxyphosphoramidate internucleoside linkages", NUCLEOTIDES AND NUCLEOTIDES, vol. 13, no. 10, January 1994 (1994-01-01), pages 2135 - 2149, XP002980323 *
QUARTIN ET AL: "Number and distribution of methylphosphonate linkages in oligodeoxynucleotides affect exo- and endonuclease sensitivity and ability to form RNase H substrates", NUCLEIC ACIDS RESEARCH, vol. 17, no. 18, November 1989 (1989-11-01), pages 7253 - 7262, XP000574936 *
SUN ET AL: "Triple-Helix Formation by alpha Oligodeoxynucleotides and alpha Oligodeoxynucleotide-Intercalator Conjugates", PROC NATL ACAD OF SCI, vol. 88, July 1991 (1991-07-01), pages 6023 - 6027, XP002979596 *
YOSHIZAWA ET AL: "Nuclease resistance of an extraordinarily thermostable mini-hairpin DNA fragment, d(GCGAAGC) and its application to in vitro protein synthesis", NUCLEIC ACIDS RESEARCH, vol. 22, no. 12, January 1994 (1994-01-01), pages 2217 - 2221, XP001084025 *
ZHAO ET AL: "Synthesis and Preliminary Biochemical Studies with 5'-Deoxy-5'-methylidyne Phosphonate Linked Thymidine Oligonucleotides", TETRAHEDRON LETTERS, vol. 37, no. 35, July 1996 (1996-07-01), pages 6239 - 6242, XP004030659 *

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9150606B2 (en) 2002-11-05 2015-10-06 Isis Pharmaceuticals, Inc. Compositions comprising alternating 2'-modified nucleosides for use in gene modulation
US9598693B2 (en) 2006-01-27 2017-03-21 Ionis Pharmaceuticals, Inc. Oligomeric compounds and compositions for the use in modulation of micrornas
US8846639B2 (en) 2008-04-04 2014-09-30 Isis Pharmaceutical, Inc. Oligomeric compounds comprising bicyclic nucleosides and having reduced toxicity
US9399774B2 (en) 2010-04-29 2016-07-26 Ionis Pharmaceuticals, Inc. Modulation of transthyretin expression
US9175291B2 (en) 2012-10-11 2015-11-03 Isis Pharmaceuticals Inc. Modulation of androgen receptor expression
US11851655B2 (en) 2013-05-01 2023-12-26 Ionis Pharmaceuticals, Inc. Compositions and methods for modulating apolipoprotein (a) expression
US9382540B2 (en) 2014-05-01 2016-07-05 Isis Pharmaceuticals, Inc Compositions and methods for modulating angiopoietin-like 3 expression

Also Published As

Publication number Publication date
JP2005504020A (en) 2005-02-10
EP1499627A2 (en) 2005-01-26
CA2452458A1 (en) 2003-01-16
WO2003004602A2 (en) 2003-01-16

Similar Documents

Publication Publication Date Title
WO2003004602A3 (en) Nuclease resistant chimeric oligonucleotides
WO2003011219A3 (en) Mediators of hedgehog signaling pathways, compositions and uses related thereto
CA2359180A1 (en) Method and medicament for inhibiting the expression of a given gene
WO2004044133A3 (en) Modified oligonucleotides for use in rna interference
WO2001026644A3 (en) Mediators of hedgehog signaling pathways, compositions and uses related thereto
AU2002218413A1 (en) Glyphosate resistant transgenic sugar beet characterised by a specific transgene insertion (t227-1), methods and primers for the detection of said insertion
CA2266748A1 (en) Three component chimeric antisense oligonucleotides
EP1417351A4 (en) ANTISENSE MODULATION OF APOLIPOPROTEIN EXPRESSION (A)
WO2001055370A3 (en) MODULATION OF OLIGONUCLEOTIDE CpG-MEDIATED IMMUNE STIMULATION BY POSITIONAL MODIFICATION OF NUCLEOSIDES
AU2171501A (en) Improvements relating to double-stranded rna inhibition
WO2002030421A3 (en) Mediators of hedgehog signaling pathways, compositions and uses related thereto
WO2003027313A3 (en) SUPPRESSORS OF CpG OLIGONUCLEOTIDES AND METHODS OF USE
WO2002028891A3 (en) Listeria inocua, genome and applications
AU2003257786A1 (en) Process for the preparation of 4, 1', 6'-trichloro-4, 1', 6'-trideoxygalactosucrose
IL159927A0 (en) Parallel or antiparallel, homologous or complementary binding of nucleic acids or analogues thereof to form duplex, triplex or quadruplex complexes
IL148155A0 (en) Large circular target-specific antisense nucleic acid compounds
EP1209228A3 (en) Environmental stress responsive promoter
WO2000008140A3 (en) Antisense oligonucleotides for the inhibition of vegf expression
AU9479201A (en) Alpha-substituted beta-aminoethyl phosphonates
EP1248633A4 (en) ANTISENSE MODULATION OF GLYCOGENE SYNTHASE KINASE 3 BETA EXPRESSION
MX9700643A (en) 5'-dithio-modified oligonucleotides.
WO2003057847A3 (en) METHODS AND MATERIALS FOR MODULATING ENaC-BETA
WO2003031459A3 (en) Modulation of the expression of genes dependent on stat-1
EP1248635A4 (en) ANTISENSE MODULATION OF GLYCOGEN SYNTHASE KINASE 3 ALPHA EXPRESSION
WO2002006487A3 (en) Regulatory sequences from meristematic cells

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2452458

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2003510761

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2002746811

Country of ref document: EP

Ref document number: 2002316502

Country of ref document: AU

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWP Wipo information: published in national office

Ref document number: 2002746811

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2002746811

Country of ref document: EP

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载